ADHD Medication Update: New Treatments and Guidelines for
Quick Facts
New ADHD Medications in 2026
Non-Stimulants
- Centanafadine ER: Triple reuptake inhibitor (norepinephrine, dopamine, serotonin) in late-stage clinical trials. A new mechanism of action with potentially lower abuse potential than stimulants.
- Viloxazine ER (Qelbree): Selective norepinephrine reuptake inhibitor. FDA-approved for children (2021) and adults (2022), gaining wider adoption.
- Mazindol ER: Investigational sympathomimetic agent being studied for ADHD with a distinct pharmacological profile. Clinical trials ongoing.
Digital
- EndeavorRx: First FDA-cleared prescription digital therapeutic for children 8-12 with ADHD, delivered as a video game-based intervention.
- Additional digital tools: Several digital ADHD interventions are in clinical development for broader age groups.
DEA has increased production quotas for ADHD medications in response to ongoing shortages. Supply is expected to continue normalizing through 2026.
Guidelines for Adults and Women
Adult ADHD
- DSM-5 broadened age-of-onset criteria to symptoms present before age 12
- Approximately 70% of adults with ADHD have at least one comorbid condition
- ADHD is associated with significant economic costs, estimated at over $100 billion annually in lost US productivity
Women
- More likely to present with inattentive symptoms and emotional dysregulation
- Hormonal fluctuations can affect ADHD symptoms (menstrual cycle, perimenopause)
- Research indicates women are typically diagnosed several years later than men on average
Best Treatment Approach
Medication Order
- Stimulant (methylphenidate or amphetamine)
- Alternative stimulant class
- Non-stimulant (atomoxetine, viloxazine, guanfacine, or centanafadine if approved)
- Adjunct: digital therapeutics, CBT
Lifestyle
- Exercise: Research suggests acute exercise can improve attention and executive function for several hours
- Sleep: Optimize sleep — studies estimate 50-75% of ADHD patients have sleep difficulties
- Diet: Mediterranean-style diet and omega-3 supplementation may offer modest benefits
- Mindfulness: Studies indicate mindfulness-based interventions can meaningfully reduce ADHD symptoms in some patients
All ADHD medications require medical supervision. Monitor heart rate, blood pressure, and weight regularly.
Frequently Asked Questions
Long-term studies spanning over a decade generally support the safety of ADHD medications with appropriate monitoring. Growth concerns in children are typically modest and may resolve over time.
ADHD begins in childhood but is frequently not diagnosed until adulthood, especially in women and those with predominantly inattentive symptoms.
Different drug classes (amphetamine vs methylphenidate). Both are approximately 70-80% effective according to clinical studies. Individual response varies, so trying both classes may be necessary.
Low when prescribed and taken as directed. Research suggests that appropriate ADHD treatment may actually reduce the risk of later substance use disorders.
Behavioral therapy can help, especially for mild ADHD. Medication is generally most effective for moderate-severe symptoms. Combined treatment (medication plus therapy) is considered the gold standard.
References
- Cortese S, et al. Comparative efficacy and tolerability of medications for ADHD. Lancet Psychiatry. 2018;5(9):727-738.
- Faraone SV, et al. The World Federation of ADHD International Consensus Statement. Neurosci Biobehav Rev. 2021;128:789-818.
- Kooij JJS, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14-34.
- MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for ADHD. Arch Gen Psychiatry. 1999;56(12):1073-1086.
- Kollins SH, et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD). Lancet Digit Health. 2020;2(4):e168-e178.